OVARIAN SUPPRESSION
FOR BREAST CANCER
Ovarian function suppression — by monthly injection (goserelin or leuprolide) or surgical removal of the ovaries — is the key step that makes aromatase inhibitors effective in premenopausal women, and provides the most powerful adjuvant endocrine therapy available for high-risk premenopausal ER-positive breast cancer.
analyticsAt a Glance
- check_circleThe SOFT and TEXT trials demonstrated that OFS + exemestane reduces recurrence risk by 34% vs tamoxifen alone in high-risk premenopausal ER+ breast cancer
- check_circleGoserelin (Zoladex) and leuprolide (Lupron) are GnRH agonists given by monthly or 3-monthly subcutaneous injection
- check_circleSurgical oophorectomy provides permanent OFS — equivalent efficacy with no ongoing injection burden but permanent menopause
- check_circleOFS causes a chemical menopause — hot flushes, bone loss, and sexual side effects are more pronounced than with tamoxifen alone
Why Ovarian Suppression Is a Critical Component of Premenopausal Endocrine Therapy
In premenopausal women, the ovaries produce large quantities of oestrogen through the HPG axis — the hypothalamus releases GnRH, which signals the pituitary to release LH and FSH, which in turn stimulate ovarian oestrogen production. Aromatase inhibitors only block peripheral oestrogen production from androgens — they have no effect on this ovarian pathway. Without stopping ovarian oestrogen production first, giving an aromatase inhibitor to a premenopausal woman is ineffective and potentially counterproductive.
“An aromatase inhibitor without ovarian suppression in a premenopausal woman is like switching off the lights in one room while the rest of the house stays lit. OFS turns off the primary power source.”
The SOFT and TEXT Trials: The Evidence That Changed Practice
The SOFT trial randomised premenopausal ER+ breast cancer patients to tamoxifen alone, tamoxifen + OFS, or exemestane + OFS. TEXT compared exemestane + OFS to tamoxifen + OFS. The combined SOFT-TEXT analysis showed: OFS + exemestane achieved the highest disease-free survival, particularly in patients who had received prior chemotherapy — a group at high risk of residual premenopausal oestrogen despite apparently being in menopause.
Who Needs OFS?
Not all premenopausal ER+ patients need OFS. It is most beneficial in high-risk patients — those who received neoadjuvant/adjuvant chemotherapy and remained premenopausal afterwards, node-positive disease, high-grade tumours (Grade 3), or young age at diagnosis (<35 years). Standard-risk premenopausal patients (node-negative, low-grade, low genomic risk) may do equally well with tamoxifen alone.
SOFT and TEXT Trial Results: OFS Combinations vs Tamoxifen Alone
The combined SOFT-TEXT analysis provides the definitive evidence base for OFS recommendations in premenopausal ER-positive breast cancer.
SOFT/TEXT Combined Analysis — 8-Year Disease-Free Survival (Chemotherapy Subgroup)
Source: Pagani O et al., Lancet Oncol 2019; patients who received prior chemotherapy and remained premenopausal
- Exemestane + OFS: 8-year DFS77.0%
- Tamoxifen + OFS: 8-year DFS71.2%
- Tamoxifen alone: 8-year DFS65.1%
- OFS + exemestane vs tamoxifen alone — absolute DFS benefit+11.9%
GnRH Agonists vs Surgical Oophorectomy: Choosing the Right OFS Method
The decision between reversible medical OFS (GnRH agonists) and permanent surgical OFS (oophorectomy) involves considerations of efficacy, tolerability, fertility preservation, BRCA status, and patient preference.
| Parameter | GnRH Agonists (Goserelin / Leuprolide) | Surgical Oophorectomy (Bilateral) |
|---|---|---|
| Mechanism | Pituitary downregulation → FSH/LH suppression → ovarian oestrogen suppression | Permanent removal of both ovaries — immediate oestrogen elimination |
| Reversibility | Reversible — ovarian function recovers within 3–6 months of stopping | Permanent — irreversible menopause |
| Efficacy | Equivalent when compliant — serum oestradiol should reach post-menopausal levels (<30 pmol/L) | Equivalent — immediate and reliable suppression without compliance dependency |
| Fertility implications | Fertility potentially preserved after OFS course ends — discussed with fertility specialist before starting | Permanently infertile after bilateral oophorectomy |
| BRCA1/2 status | BRCA carriers may prefer surgical oophorectomy — which also reduces ovarian cancer risk (risk-reducing salpingo-oophorectomy) | Strongly recommended for BRCA1 carriers by age 35–40 — dual benefit: OFS and ovarian cancer risk reduction |
| Administration | Monthly (3.6 mg) or 3-monthly (10.8 mg) subcutaneous implant injection | Single surgical procedure (laparoscopic) — day-case surgery |
| Compliance burden | Monthly/quarterly injection visits for the planned treatment duration (2–5 years) | One-time procedure — no ongoing compliance required |
| Hot flushes (comparative) | Equivalent — very common in both; may be more abrupt at GnRH agonist initiation | Abrupt onset — no gradual adaptation period as with GnRH agonist |
| Cost | Monthly injections have ongoing cost throughout treatment duration | Single procedural cost — may be cost-effective over 5-year treatment course |
Starting Ovarian Suppression: What to Expect
The first weeks of OFS are the most symptomatic — understanding the expected transition helps patients prepare.
- 1
Before the First Injection: Confirming Premenopausal Status
LH, FSH, and serum oestradiol are measured before starting OFS to confirm premenopausal status — particularly in patients who have received chemotherapy, which may transiently suppress periods without causing true menopause.
- 2
Initial Testosterone Flare
GnRH agonists cause an initial 7–14 day flare of LH and FSH before the pituitary becomes downregulated — temporarily increasing oestrogen in the first 1–2 weeks. This flare can transiently worsen tumour-related symptoms in some patients. Anti-androgen co-administration can prevent this in prostate cancer; in breast cancer, the flare effect is generally clinically insignificant but worth knowing about.
- 3
Suppression Achieved by Week 3–4
Serum oestradiol falls to post-menopausal levels by the end of the first month. Hot flushes, vaginal dryness, and mood changes typically emerge at this point — the chemical menopause begins.
- 4
Confirm Suppression at 3 Months
Serum oestradiol should be measured at 3 months to confirm adequate suppression (target <30 pmol/L). If oestrogen has not been adequately suppressed, injection timing or dose frequency may need adjustment. Do not start the aromatase inhibitor until suppression is confirmed.
- 5
Ongoing Monitoring Every 6 Months
Serum oestradiol at 6-monthly intervals ensures ongoing suppression — particularly important in patients under 40, whose ovaries may partially 'escape' GnRH agonist suppression. DEXA scan at baseline and every 2 years for bone density monitoring.
Managing OFS Side Effects: The Most Challenging Part of This Treatment
OFS causes a chemical menopause — the side effects are those of menopause, typically more severe and abrupt than natural menopause, and compounded by an AI if exemestane is co-prescribed.
Expected — Manageable
- Hot flushesVery common but manageable — venlafaxine 75 mg has the best evidence; gabapentin is an alternative. Oxybutynin 5 mg at night specifically reduces night sweats.
- Mood changesIrritability, low mood, and anxiety are common in the first 3–6 months. Psychological support and exercise are first-line; antidepressants if needed (venlafaxine preferred with AIs — no CYP2D6 issue).
- Reduced libidoVery common with OFS — oestrogen deprivation reduces libido, vaginal lubrication, and genital sensitivity. Vaginal lubricants help; specialist psychosexual support for significant distress.
- Vaginal drynessNon-hormonal vaginal moisturisers (Replens, YES) used 3× weekly; lubricants for intercourse. Low-dose local vaginal oestrogen is generally considered safe in ER+ breast cancer — discuss with oncologist.
Requires Active Management
- Bone density loss — monitoring requiredDEXA at baseline and every 2 years. Calcium 1,200 mg + vitamin D 800 IU daily. If T-score falls below –2.0, zoledronic acid 4 mg IV 6-monthly or denosumab 60 mg SC 6-monthly.
- Joint pain and stiffnessPronounced with OFS + AI — graded exercise, NSAIDs, vitamin D repletion. Switch from exemestane to tamoxifen + OFS if intolerable — less arthralgia with tamoxifen.
- Cardiovascular risk with long-term OFSOestrogen deprivation increases cardiovascular risk over time. Exercise, lipid monitoring, blood pressure check, and smoking cessation counselling at every visit.
- Cognitive effectsOFS can impair verbal memory and concentration — documented in short-term studies. Usually mild and reversible; screen for depression as a contributing factor; neuropsychological support if significantly affecting work.
More from the Hormone Therapy Resource Library
Continue exploring endocrine therapy for breast cancer — from receptor status to drug-specific guides.
- What Is Hormone Therapy for Cancer and How Does It Work?
- ER, PR, and HER2 Status Explained: What the Results Mean
- Tamoxifen: Side Effects, CYP2D6 Interactions, and Monitoring
- Aromatase Inhibitors: Letrozole, Anastrozole, and Exemestane
- Hormone Therapy for Breast Cancer — Complete Guide
- CDK4/6 Inhibitors in Breast Cancer
Frequently Asked Questions
Common questions from premenopausal patients receiving or considering ovarian suppression.
About Ovarian Suppression
I want to have children after breast cancer treatment — can I still have OFS and preserve my fertility?
Yes — if OFS is delivered via GnRH agonist injections (goserelin or leuprolide) rather than surgical oophorectomy, ovarian function can recover after treatment ends, and pregnancy is possible. The POSITIVE trial demonstrated that a planned interruption of endocrine therapy for up to 2 years to allow pregnancy did not significantly increase early recurrence risk in selected patients. Importantly, fertility preservation — egg or embryo freezing before chemotherapy and OFS begins — should be discussed before any treatment starts. Delaying OFS by 2–4 weeks for egg retrieval does not compromise breast cancer outcomes and provides insurance for future fertility. This conversation should happen at diagnosis, not after treatment has started.
I am BRCA1-positive and my oncologist has suggested surgical oophorectomy — is this appropriate?
Yes — bilateral risk-reducing salpingo-oophorectomy (RRSO) is specifically recommended for BRCA1 carriers by age 35–40 because it reduces ovarian cancer risk by approximately 80–90% in addition to providing permanent OFS for breast cancer treatment. BRCA1-associated ovarian cancer is highly lethal and currently lacks an effective screening programme — surgical prevention is strongly preferred over surveillance. For a premenopausal BRCA1 breast cancer patient who would otherwise be receiving GnRH agonist OFS for 5 years anyway, RRSO provides both risk reductions simultaneously. Discuss with both your breast oncologist and a clinical geneticist experienced in BRCA-related management.
How do I know if my ovaries are actually being suppressed by goserelin?
Serum oestradiol measurement is the definitive test — your target while on GnRH agonist OFS is an oestradiol level below 30 pmol/L (post-menopausal range). This should be checked at 3 months after initiating OFS and then every 6 months. Some women — particularly those under 40 — have ovaries that partially 'escape' suppression on monthly goserelin, with oestradiol levels rising above the target between injections. If this happens, switching to 3-monthly depot goserelin (10.8 mg) or adding a second GnRH agonist dose, or switching to surgical OFS, are the options. Do not assume suppression is adequate without a confirmed oestradiol level.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Ovarian Suppression for Your Breast Cancer?
CancerFax connects premenopausal ER-positive breast cancer patients with specialist oncologists who can review the SOFT/TEXT trial evidence, assess whether OFS is indicated for your risk level, and discuss the injection vs surgical approach based on your specific situation and fertility intentions.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.